Send to

Choose Destination
See comment in PubMed Commons below
World J Stem Cells. 2013 Oct 26;5(4):149-62. doi: 10.4252/wjsc.v5.i4.149.

Aiming to immune elimination of ovarian cancer stem cells.

Author information

Jiabo Di, Tjitske Duiveman-de Boer, Carl G Figdor, Ruurd Torensma, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, GA 6525 Nijmegen, The Netherlands.


Ovarian cancer accounts for only 3% of all cancers in women, but it causes more deaths than any other gynecologic cancer. Treatment with chemotherapy and cytoreductive surgery shows a good response to the therapy. However, in a large proportion of the patients the tumor grows back within a few years. Cancer stem cells, that are less responsive to these treatments, are blamed for this recurrence of disease. Immune therapy either cellular or humoral is a novel concept to treat cancer. It is based on the notice that immune cells invade the tumor. However, the tumor invest heavily to escape from immune elimination by recruiting several immune suppressive mechanisms. These processes are normally in place to limit excessive immune activation and prevent autoimmune phenomena. Here, we discuss current knowledge about the immune (suppressive) status in ovarian cancer. Moreover, we discuss the immunological targets of ovarian cancer stem cells.


Cancer stem cell; Immune suppression; Immune therapy; Ovarian cancer; Tumor microenvironment

PubMed Commons home

PubMed Commons


    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center